Back to Search
Start Over
EARLY SAFETY AND EFFICACY DATA FROM A PHASE I/II TRIAL OF DZD4205, A SELECTIVE JAK1 INHIBITOR, IN RELAPSED/REFRACTORY PERIPHERAL T‐CELL LYMPHOMA
- Source :
- Hematological Oncology. 39
- Publication Year :
- 2021
- Publisher :
- Wiley, 2021.
Details
- ISSN :
- 10991069 and 02780232
- Volume :
- 39
- Database :
- OpenAIRE
- Journal :
- Hematological Oncology
- Accession number :
- edsair.doi...........4746919dd8a451195304bd2a645f9237
- Full Text :
- https://doi.org/10.1002/hon.57_2879